If you enjoy this content, please share it with a colleague
Elekta
For almost five decades, Elekta has been a leader in precision radiation medicine. Our nearly 4,000 employees worldwide are committed to ensuring everyone in the world with cancer has access to – and benefits from – more precise, personalized radiotherapy treatments. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm Exchange. Visit elekta.com or follow @Elekta on Twitter.
RELATED CONTENT
Elekta and Sunnybrook Health Sciences Centre have initiated installation of Elekta’s MR-linac, an investigational magnetic resonance radiation therapy (MR/RT) system at the Odette Cancer Centre, Sunnybrook Health Sciences Centre in Toronto.
Due to its widespread success in treating several types of brain cancer, global market growth for Gamma Knife radiosurgery involving the head is expected to exceed $364.8 million by 2025. As more patients seek treatment at facilities that offer Gamma Knife radiosurgery, the market is forecast to grow at a compound annual growth rate (CAGR) of 9.2 percent, according to a new report from public relations firm OpenPR.
Stereotactic body radiation therapy (SBRT) employs significantly higher per fraction radiation doses than conventional radiotherapy. Therefore, for patients with aggressive cancers, SBRT can be a more potent, therapeutic treatment option leading to better local control. However, an enduring challenge in delivering SBRT for some cancers — lung and liver tumors for instance — has been the impact of the patient’s breathing on tumor motion.
According to the National Institutes of Health (NIH), precision-based medicine is an emerging approach for disease ...
Up to 45 percent of all cancer patients develop brain metastases, tumors that spread to the brain from cancers located elsewhere in the body. As the number of patients affected by metastatic brain tumors grows, targeted treatment options, like the Gamma Knife radiosurgery, may offer better tumor control and symptom management.
The University Medical Centre (UMC) Utrecht in the Netherlands recently treated the first patient as part of a clinical study with the Elekta Unity magnetic resonance radiation therapy (MR/RT) system. Elekta Unity is capable of delivering precisely targeted radiation doses and capturing MR images of diagnostic quality. It is the first time a patient has been treated on a state-of-the-art linear accelerator with a high-field MR imaging system, according to Elekta.
April 26, 2017 — A new report on the brain cancer diagnostics market projects that up to 78,000 new cases of primary ...
Elekta announced that its Leksell Vantage Stereotactic System, will be highlighted at the American Association of Neurological Surgeons (AANS) Annual Meeting, April 22-26 in Los Angeles. Leksell Vantage is the company's next-generation system for target localization and coordinate referencing for precision neurosurgery. The system’s head frame is constructed of a novel epoxy composite and is designed to improve imaging quality, speed and patient comfort in neurosurgery procedures.
Elekta announced new data demonstrating Leksell Gamma Knife better spares healthy brain tissue and delivers a higher radiation dose compared to linear accelerator (linac)-based delivery methods. The results, evaluating patients undergoing radiosurgery for large or complex brain tumors, were published in the Journal of Neurosurgery.
On Dec. 8, 2016, a female patient in her 60s became the first in the Australia/New Zealand region to receive electronic brachytherapy to treat her skin cancer lesion, a basal cell carcinoma on her nose. Radiation Oncology Centres (ROC) physicians in Brisbane used their new Esteya electronic brachytherapy system from Elekta to deliver the patient’s first of six non-invasive treatments. Esteya is a form of high dose rate (HDR) brachytherapy that applies high-precision radiation therapy directly to the cancer site, reducing radiation to surrounding healthy tissues.